Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Dr. Peter Attia

👤 Speaker
11186 total appearances

Appearances Over Time

Podcast Appearances

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That was a stage four?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That was a stage four?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

This is a median survival study. You're not doing overall survival, correct?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

This is a median survival study. You're not doing overall survival, correct?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

I feel like it was eight more months of median survival. Does that sound about right?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

I feel like it was eight more months of median survival. Does that sound about right?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

Now, at this point, I'm in medical school just down the street. I'm at Stanford. And I remember we had a big discussion about this. I'm in my first year of medical school. And the discussion we had in class was, I think at the time Avastin was $100,000 for the treatment. Extends median survival by whatever, but I think it was eight months.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

Now, at this point, I'm in medical school just down the street. I'm at Stanford. And I remember we had a big discussion about this. I'm in my first year of medical school. And the discussion we had in class was, I think at the time Avastin was $100,000 for the treatment. Extends median survival by whatever, but I think it was eight months.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

The UK said, no, the NHS said, we are not paying for this because at the time the NHS had this $100,000 quality adjusted life year hurdle, which is understandable, right? That's how you throttle supply side economics. They said, look, we can't pay for a drug. We can't pay more than $100,000 for an incremental year of quality adjusted life year. This is only giving you eight months.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

The UK said, no, the NHS said, we are not paying for this because at the time the NHS had this $100,000 quality adjusted life year hurdle, which is understandable, right? That's how you throttle supply side economics. They said, look, we can't pay for a drug. We can't pay more than $100,000 for an incremental year of quality adjusted life year. This is only giving you eight months.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That's why I know it was less than 12. And so the NHS flatly said, we're not paying for this. And I do believe people in the UK could pay out of pocket for it.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That's why I know it was less than 12. And so the NHS flatly said, we're not paying for this. And I do believe people in the UK could pay out of pocket for it.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That's right. People in Canada could not because you couldn't have private insurance in Canada, though you could come to the US for treatment. So of course, this just became a great topic of discussion for med school freshmen. What was your thought at the time of, have we moved the needle enough? How do we think about the economics of this?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

That's right. People in Canada could not because you couldn't have private insurance in Canada, though you could come to the US for treatment. So of course, this just became a great topic of discussion for med school freshmen. What was your thought at the time of, have we moved the needle enough? How do we think about the economics of this?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

Did you go straight from Genentech to being a chancellor at UCSF? Just because I want to stay with the story, I want to continue the arc of your career. We're at the halfway point, right? We're one third of the way into- Early days. Yeah, yeah, yeah.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

Did you go straight from Genentech to being a chancellor at UCSF? Just because I want to stay with the story, I want to continue the arc of your career. We're at the halfway point, right? We're one third of the way into- Early days. Yeah, yeah, yeah.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

How did you, given you are truly on the cusp of what is happening in oncology and biotechnology, and now the same institution that said- you can't come back here to have a clinical appointment after saving the people of Uganda is now offering you the highest post essentially outside of a provost, I'm guessing, right? I don't even know where the chance- It is the highest post.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

How did you, given you are truly on the cusp of what is happening in oncology and biotechnology, and now the same institution that said- you can't come back here to have a clinical appointment after saving the people of Uganda is now offering you the highest post essentially outside of a provost, I'm guessing, right? I don't even know where the chance- It is the highest post.

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

It is the highest post. Okay. So that's kind of remarkable. And does that just speak to what they saw as the vision of that institution, which was few people have learned what Sue has learned in the last 10 years, and we want that type of leadership here?

The Peter Attia Drive
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

It is the highest post. Okay. So that's kind of remarkable. And does that just speak to what they saw as the vision of that institution, which was few people have learned what Sue has learned in the last 10 years, and we want that type of leadership here?